A daily pill previously shown to slow the progression of type 1 diabetes has now shown a loss of therapeutic benefit when stopped—affirming the promise of the treatment.

In 2023, an Australian trial reported that a daily pill of baricitinib—commonly prescribed for rheumatoid arthritis and alopecia—could safely preserve the body's own insulin production and slow the development of type 1 diabetes in those recently diagnosed.

Now, a follow-up trialpresented at the Annual Meeting of the European Association for the Study of Diabetes, held in Vienna this week, has revealed that once baricitinib treatment was stopped, participants' diabetes progressed.

They were found to produce less insulin and had less stable blood sugar levels, which were not significantly different from those on the plac

See Full Page